Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Lips

Showing results (61-70 of 121) with videos related to

Pageof 13
Sort By:
Nature Reviews. Cancer|October 19, 2022
Learning to distinguish progressive and non-progressive ductal carcinoma in situAnna K Casasent, Mathilde M Almekinders, Charlotta Mulder, et al.
Breast Cancer Research and Treatment|August 8, 2019
Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort studyGurdeep S Mannu, Emma J Groen, Zhe Wang, et al.
Breast Cancer Research and Treatment|December 4, 2012
SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancerJorma J de Ronde, Esther H Lips, Lennart Mulder, et al.
Nature Reviews. Cancer|December 15, 2022
Author Correction: Learning to distinguish progressive and non-progressive ductal carcinoma in situAnna K Casasent, Mathilde M Almekinders, Charlotta Mulder, et al.
Breast Cancer Research : BCR|October 5, 2015
Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy responseEsther H Lips, Magali Michaut, Marlous Hoogstraat, et al.
Breast Cancer Research and Treatment|May 15, 2013
Platform comparisons for identification of breast cancers with a BRCA-like copy number profilePhilip C Schouten, Ewald van Dyk, Linde M Braaf, et al.
Breast (Edinburgh, Scotland)|March 3, 2020
The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic reviewSena Alaeikhanehshir, Ellen G Engelhardt, Frederieke H van Duijnhoven, et al.
Molecular Oncology|February 15, 2020
Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplificationMieke R Van Bockstal, Marie Colombe Agahozo, Ronald van Marion, et al.
Breast Cancer Research and Treatment|July 27, 2015
The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measureM Jebbink, E van Werkhoven, I A M Mandjes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2018
Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma <i>In Situ</i>-A Nested Case-Control StudyLindy L Visser, Lotte E Elshof, Michael Schaapveld, et al.
Pageof 13

Showing results (61-70 of 121) with videos related to

Sort By:
Pageof 13
Nature Reviews. Cancer|October 19, 2022
Learning to distinguish progressive and non-progressive ductal carcinoma in situAnna K Casasent, Mathilde M Almekinders, Charlotta Mulder, et al.
Breast Cancer Research and Treatment|August 8, 2019
Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort studyGurdeep S Mannu, Emma J Groen, Zhe Wang, et al.
Breast Cancer Research and Treatment|December 4, 2012
SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancerJorma J de Ronde, Esther H Lips, Lennart Mulder, et al.
Nature Reviews. Cancer|December 15, 2022
Author Correction: Learning to distinguish progressive and non-progressive ductal carcinoma in situAnna K Casasent, Mathilde M Almekinders, Charlotta Mulder, et al.
Breast Cancer Research : BCR|October 5, 2015
Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy responseEsther H Lips, Magali Michaut, Marlous Hoogstraat, et al.
Breast Cancer Research and Treatment|May 15, 2013
Platform comparisons for identification of breast cancers with a BRCA-like copy number profilePhilip C Schouten, Ewald van Dyk, Linde M Braaf, et al.
Breast (Edinburgh, Scotland)|March 3, 2020
The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic reviewSena Alaeikhanehshir, Ellen G Engelhardt, Frederieke H van Duijnhoven, et al.
Molecular Oncology|February 15, 2020
Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplificationMieke R Van Bockstal, Marie Colombe Agahozo, Ronald van Marion, et al.
Breast Cancer Research and Treatment|July 27, 2015
The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measureM Jebbink, E van Werkhoven, I A M Mandjes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2018
Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma <i>In Situ</i>-A Nested Case-Control StudyLindy L Visser, Lotte E Elshof, Michael Schaapveld, et al.
Pageof 13